Literature DB >> 10854350

Pharmacologic treatment of essential tremor.

W C Koller1, A Hristova, M Brin.   

Abstract

Essential tremor (ET) is a common movement disorder that often causes functional disability, potentially leading to physical and emotional difficulties. The paucity of data available regarding the underlying pathophysiologic mechanism of ET hinders the development of innovative approaches to pharmacotherapeutic treatments. Options for drug therapy include the use of primidone, beta-adrenergic blockers, such as propranolol, alcohol, and other drugs, such as benzodiazepines, gabapentin, carbonic anhydrase inhibitors, clozapine, flunarizine, clonidine, and the methylxanthine derivative theophylline. Chemodenervation with botulinum toxin type A may be a therapeutic option for selected patients with ET. Each drug is classified as to the quality of evidence for efficacy and the suggested strength of therapeutic recommendation. In general clinical practice, primidone and propranolol have proven efficacy in ET.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854350

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  Neuropsychological and quality of life outcomes 12 months after unilateral thalamic stimulation for essential tremor.

Authors:  J A Fields; A I Tröster; S P Woods; C I Higginson; S B Wilkinson; K E Lyons; W C Koller; R Pahwa
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-03       Impact factor: 10.154

Review 2.  Management of essential tremor.

Authors:  Theresa A Zesiewicz; Elmyra Encarnacion; Robert A Hauser
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

Review 3.  Beneficial Extracardiac Effects of Cardiovascular Medications.

Authors:  Asra K Butt; Jay Patel; Hamid Shirwany; Qasim Mirza; Jonathan Hoover; Rami N Khouzam
Journal:  Curr Cardiol Rev       Date:  2022

Review 4.  Benefits and risks of pharmacological treatments for essential tremor.

Authors:  Kelly E Lyons; Rajesh Pahwa; Cynthia L Comella; Mahmood S Eisa; Rodger J Elble; Stanley Fahn; Joseph Jankovic; Jorge L Juncos; William C Koller; William G Ondo; Kapil D Sethi; Matthew B Stern; Caroline M Tanner; Ron Tintner; Ray L Watts
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

5.  Objective predictors of 'early tolerance' to ventral intermediate nucleus of thalamus deep brain stimulation in essential tremor patients.

Authors:  Shabbir Hussain Merchant; Sheng-Han Kuo; Yu Qiping; Linda Winfield; Guy McKhann; Sameer Sheth; Seth L Pullman; Blair Ford
Journal:  Clin Neurophysiol       Date:  2018-06-05       Impact factor: 3.708

6.  Charcot-Marie-Tooth disease.

Authors:  Kinga Szigeti; James R Lupski
Journal:  Eur J Hum Genet       Date:  2009-03-11       Impact factor: 4.246

7.  Essential tremor is not a neurodegenerative disease.

Authors:  Ali H Rajput; Charles H Adler; Holly A Shill; Alex Rajput
Journal:  Neurodegener Dis Manag       Date:  2012-06

Review 8.  Epidemiology and management of essential tremor in children.

Authors:  Joseph Ferrara; Joseph Jankovic
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

9.  Sustained Medication Reduction Following Unilateral VIM Thalamic Stimulation for Essential Tremor.

Authors:  Andrew S Resnick; Michael S Okun; Teresita Malapira; Donald Smith; Fernando L Vale; Kelly Sullivan; Amber Miller; Israt Jahan; Theresa Zesiewicz
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-04-06

10.  The history of barbiturates a century after their clinical introduction.

Authors:  Francisco López-Muñoz; Ronaldo Ucha-Udabe; Cecilio Alamo
Journal:  Neuropsychiatr Dis Treat       Date:  2005-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.